The Pharmaceutical Oncology Initiative (POI) believes that UK cancer survival rates should be comparable with the best in Europe. Established in 2005, it has demonstrated the benefits of collaboration with partners including the Department of Health (DH) and the NHS, by facilitating major strategic projects that enable people to gain better access to cancer services and medicines.
The POI is a group of ABPI member pharmaceutical companies that have been successfully collaborating with the DH, the NHS and other key partners for 10 years to improve the delivery of cancer services and access to medicines.
In light of the changing environment within cancer care, the POI and its partners aim to address these challenges. The priority areas include:
Changing the way medicines are developed (such as delivering stratified medicines for smaller patient populations) will impact all aspects of cancer-service delivery. In particular, ensuring effective genetic services and pathology testing, which are needed for assessing whether patients are likely to respond to stratified medicines.
Cancer services must address the inequalities associated with the ageing population and changing demographics.
Comprehensive patient-level data collection has the ability to revolutionise treatment decisions. For example, the Systemic Anti-Cancer Therapy (SACT) database, which records information on chemotherapy treatment, together with the cancer-registry data, will help identify best practice and reduce geographical variation.
Optimising the use of cancer medicines to achieve the best possible patient outcomes.
To find out more about the POI, or read about future initiatives in cancer care, download the POI booklet (PDF, 2.36 MB).